The Serum Institute of India (SII) and Oxford University launched the high-efficacy malaria vaccine R21/Matrix-M in Cote d'Ivoire, priced under $4 per dose and approved by WHO.
SII plans to produce 100 million doses annually, with the vaccine also authorized in Ghana, Nigeria, Burkina Faso, and the Central African Republic, aiming to reduce malaria deaths in Africa.
